文献速递头痛与眩晕神经重症与神经感染

甲氧氯普胺联合苯海拉明治疗急性创伤后头痛的随机研究

Randomized Study of Metoclopramide Plus Diphenhydramine for Acute Posttraumatic Headache.
PubMed 文献 · Neurology · 2021-03-24

这项随机双盲安慰剂对照研究在2个城市急诊科纳入160例急性中重度创伤后头痛患者,比较静脉甲氧氯普胺20mg+苯海拉明25mg与安慰剂的疗效。结果显示联合治疗组1小时疼痛改善5.2分,安慰剂组3.8分,差异1.4分(95%CI 0.7-2.2,p<0.01),但不良事件报告率更高(43% vs 28%,p=0.04)。

要点

  • 静脉甲氧氯普胺20mg+苯海拉明25mg可显著改善急诊急性创伤后头痛的疼痛评分。
  • 联合治疗组1小时疼痛改善较安慰剂组多1.4分(95%CI 0.7-2.2)。
  • 联合治疗组不良事件报告率43%,高于安慰剂组的28%。

核心结论

  • 静脉甲氧氯普胺20mg联合苯海拉明25mg在缓解急诊创伤后头痛方面优于安慰剂。

研究设计与样本

  • 随机、双盲、安慰剂对照、平行组研究,在2个城市急诊科进行,共随机160例患者(81例联合治疗,79例安慰剂)。

主要发现

  • 安慰剂组平均疼痛改善3.8分(SD 2.6),联合治疗组改善5.2分(SD 2.3),差异1.4分(95%CI 0.7-2.2,p<0.01)。
  • 联合治疗组81例中35例(43%)报告不良事件,安慰剂组79例中22例(28%)报告不良事件(率差15%,95%CI 1-30,p=0.04)。

临床怎么用

  • 对于急诊急性中重度创伤后头痛患者,可考虑静脉甲氧氯普胺20mg联合苯海拉明25mg以改善疼痛。
  • 使用时需注意不良事件风险,联合治疗组不良事件报告率高于安慰剂组。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine whether IV metoclopramide 20 mg + diphenhydramine 25 mg (M + D) was more efficacious than IV placebo for acute moderate or severe posttraumatic headache in the emergency room. METHODS: We conducted this randomized, double-blind, placebo-controlled, parallel-group study in 2 urban emergency departments (EDs). Participants who experienced head trauma and presented to our EDs within 10 days with a headache fulfilling criteria for acute posttraumatic headache were included. We randomized participants in a 1:1 ratio to M + D or placebo. Participants, caregivers, and outcome assessors were blinded to assignment. The primary outcome was improvement in pain on a scale of 0 to 10 between baseline and 1 hour after treatment. RESULTS: This study was completed between August 2017 and March 2020. We screened 414 patients for participation and randomized 160: 81 to M + D and 79 to placebo. Baseline characteristics were comparable between the groups. All enrolled participants provided primary outcome data. Patients receiving placebo reported mean improvement of 3.8 (SD 2.6), while those receiving M + D improved by 5.2 (SD 2.3), for a difference favoring metoclopramide of 1.4 (95% confidence interval [CI] 0.7-2.2, p < 0.01). Adverse events were reported by 35 of 81 (43%) patients who received metoclopramide and 22 of 79 (28%) of patients who received placebo (95% CI 1-30 for difference of 15%, p = 0.04). CONCLUSION: M + D was more efficacious than placebo with regard to relief of posttraumatic headache in the ED. TRIAL REGISTRATION INFORMATION: ClinicalTrials.gov Identifier: NCT03220958. CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that for patients with acute moderate or severe posttraumatic headache, IV M + D significantly improved pain compared to placebo.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Friedman BW, Irizarry E, Cain D, et al. Randomized Study of Metoclopramide Plus Diphenhydramine for Acute Posttraumatic Headache. Neurology. 2021. PMID: 33762421. doi:10.1212/WNL.0000000000011822

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。